DTIL (Precision BioSciences) Institutional Ownership: 66.11% (As of Jul. 11, 2026)


DTIL Precision BioSciences Inc DTIL
50 GF Score
Price $8.77
GF Value $1.83
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Institutional Ownership?

Precision BioSciences DTIL -4.37% 50 Institutional Ownership is 66.11% as of Jul. 11, 2026. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Precision BioSciences's institutional ownership is 66.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Precision BioSciences's Insider Ownership is 28.83%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Precision BioSciences's Float Percentage Of Total Shares Outstanding is 97.43%.

Precision BioSciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Precision BioSciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precision BioSciences Institutional Ownership Chart

Precision BioSciences Historical Data

The historical data trend for Precision BioSciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.55 10.95 9.53 11.18 11.68 11.85 12.76 12.77 13.05 15.91
DTIL
50GF Score
Precision BioSciences Inc DTIL
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precision BioSciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 66.11% mean?
Precision BioSciences (DTIL) has a Institutional Ownership of 66.11% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Precision BioSciences and its competitors.
Is Precision BioSciences' Institutional Ownership too high?
Precision BioSciences' current Institutional Ownership is 66.11%. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Institutional Ownership compare to NBP and HUMA?
Precision BioSciences' Institutional Ownership of 66.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current Institutional Ownership is 66.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current Institutional Ownership is 66.11%. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current Institutional Ownership is 66.11% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

  • Institutional Ownership: 66.11%
  • GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precision BioSciences Business Description

Other Exchanges PBS0:Germany
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score

Get the complete analysis for DTIL

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77
Price
$1.83
GF Value